Chimeric antigen receptor (CAR) T cell therapy breakthroughs in cancer immunotherapy in the last decade have made CAR T cells one of the most promising fields for cancer therapies. There are dozens of emerging partnerships out there between big Pharma and specialists in the area.
The use of autologous T-cells (a patient's own) has various limitations. Advances in Allogeneic or “off-the-shelf,” CAR T cells give scale, quality and consistency benefits that make them promising commercial candidates.
Fate Therapeutics (FATE) is one of the mkt leaders that entered into a partnership with J&J last year, using a proprietary iPSC product platform for the genetic engineering of pluripotent cells for off-the-shelf cancer therapies with a host of applications:
Submitted November 25, 2021 at 05:19AM by Historical_Job_8609 https://ift.tt/3cRqqzG
